ASCIA response to FSANZ Proposal P1028 – Infant Formula Consultation Paper 3 - Regulatory framework and definitions. Lodged 20 October 2021. 
ASCIA FSANZ Infant formula response 20 October 2021950.61 KB

ASCIA responded to a request for information from the Australian Technical Advisory Group on Immunisation (ATAGI) on 24 September 2021. On 8 October 2021 ATAGI  released a statement, prepared in consultation with ASCIA, on the use of a third primary ‘booster’ dose of COVID-19 vaccine in severely immunocompromised people, including people with primary immunodeficiencies.  
https://www.health.gov.au/news/atagi-statement-on-the-use-of-a-3rd-primary-dose-of-covid-19-vaccine-in-individuals-who-are-severely-immunocompromised

ASCIA response to National Blood Authority (NBA) call for public comments on the draft Acute Transfusion Reaction Guidelines. Lodged online 2 July 2021.

www.nationalimmunodeficiencystrategy.org.au/

ASCIA response to dupilumab (Dupixent®) application for severe uncontrolled asthma (included in the November 2020 PBAC meeting agenda). Lodged 21 September 2020.
ASCIA letter PBAC re Dupilumab 2020-09-2147.86 KB

ASCIA pre-budget submission. Lodged 24 August. This is an amended version of the submission lodged in January 2020. ASCIA Pre-Budget Submission 2020-2021 2020-08-24 400.83 KB

ASCIA letter to the Minister for Health (Hon Greg Hunt MP) and Chief Medical Officer (Professor Brendan Murphy), regarding the potential of immune blockers in treatment of COVID-19. Submitted 5 May 2020. A response was received on 10 June 2020. As of  August 2021 there are now shortages in Australia of Tociluzumab, an immune blocker which is being used internationally to treat COVID-19.
ASCIA letter AU Govt re COVID19 Treatments 20200505 146.09 KB 
IL-6_as_a_marker_of_outcome_in_COVID-19160.65 KB 
Siltuximab_COVID-19_Italy531.28 KB 
Tociluzumab_COVID-19_China1.64 MB

ASCIA letter to PBAC regarding concerns about revised PBS listings for antibiotics and patients with immunodeficiencies. Submitted 27 April 2020.  ASCIA letter PBAC Immunodeficiencies Antibiotics 2020-04-2786.61 KB  Changes were made on 1 May 2020 to allow patients who require prolonged oral antibiotic therapy to access an increased maximum quantity and/or repeat(s), as described in Revised PBS listings for Antibiotic use

ASCIA letter to PBAC regarding access to adrenaline (epinephrine) auto-injectors on the PBS. Submitted 24 April 2020. ASCIA letter PBAC Anaphylaxis Adrenaline 20200424131.90 KB

Joint letter from A&AA, ASCIA, National Allergy Strategy and CFAR to the Ministerial Forum on Food Regulation and FSANZ P1053. Submitted 30 April 2020. Ministerial Forum P1053 Final 300420753.65 KB  FSANZ has responded that they will continue to consider allergen management within the scope of the chapter 3 review as the project progresses.

ASCIA letter to the Minister for Health (Hon Greg Hunt MP), regarding telehealth changes. Submitted 7 April 2020. 
ASCIA Letter Hon Greg Hunt 20200407137.54 KB Changes to telehealth have since been made, effective 20 April 2020. www.allergy.org.au/members/covid-19#cd4

ASCIA letter to PBAC regarding dupilumab submission for atopic dermatitis. Submitted 2 March 2020. 
ASCIA letter PBAC Dupilumab 2020030275.35 KB  Dupilumab has been recommended by the PBAC for PBS listing. For details refer to the announcement here.

ASCIA submission to FSANZ  Plain English Labelling (PEAL) proposal P1044. Submitted 27 February 2020. 
ASCIA FSANZ P1044 Submission 2020 02 27160.82 KB

ASCIA pre-budget 2020-2021 submission. Submitted 10 January 2020. 
ASCIA Pre-Budget Submission 2020-2021808.7 KB

ASCIA opening statement to the public hearing in Sydney on 19 November 2019 for the Parliamentary Inquiry into Allergies and Anaphylaxis. ASCIA opening statement parliamentary inquiry 19-11-19 

ASCIA submission to the Parliamentary Inquiry into Allergies and Anaphylaxis. Submitted 24 October 2019.
ASCIA Submission Parliamentary Inquiry 24-10-19 or on the government website at Submission 153. The Inquiry report was tabled on 15 June 2020 in the Parliament of the Commonwealth of Australia.  Walking the allergy tightrope1.15 MB 

ASCIA response to National Blood Authority (NBA) request for information regarding Berinert. Submitted 4 September 2019.
ASCIA letter NBA Berinert 20190904359.77 KB

Feedback to Australian National Breastfeeding Strategy. Submitted 5 August 2019, further to submissions on 30 November 2018 and 18 June 2018. ASCIA response Australian National Breast Feeding Strategy 20190805203.32 KB This request was successful.

ASCIA application to the Medical Services Advisory Committee (MSAC) for a food allergen challenge Medical Benefits Schedule (MBS) item number. Submitted 18 July 2019. This submission was unsuccessful.

 ASCIA submission to Consultation on the Draft National Clinical Quality Registry Strategy. Submitted 20 June 2019.

ASCIA submission to the Food Standards Australia New Zealand (FSANZ) Review of Food Standards Code chapter 3 and 4 – Food Safety Management Requirements (Australia only). Submitted 14 June 2019.
ASCIA submission FSANZ 14-06-201989.03 KB

ASCIA response to Pharmaceutical Benefits Advisory Committee (PBAC) request for information regarding Dupilumab. Submitted 30 May 2019.  ASCIA letter PBAC Dupilumab 20190530172.30 KB  This submission was unsuccessful, but Dupilumab has since been recommended by the PBAC for PBS listing. For details refer to the announcement here.

 ASCIA letter to National Blood Authority (NBA) regarding BloodSTAR issues. Submitted 27 May 2019. ASCIA letter NBA BloodSTAR 20190527 152.92 KB  The NBA has responded and will follow up on the issues raised in the ASCIA letter.

ASCIA response to new Medicare Benefits Schedule (MBS) Review Specialist and Consultant Physician Consultation Clinical Committee of the MBS Review Taskforce. Submitted 25 March 2019. 

ASCIA letter to the Royal Australasian College of Physicians (RACP) President requesting Therapeutic Goods Authority (TGA) Authorised Prescriber (AP) endorsements. Submitted 28 February 2019.  ASCIA letter RACP President 2019022876.31 KB  This request was unsuccessful, however the TGA has since changed the AP process.